About STEQEYMA IV

STEQEYMA IV is a prescription medication containing the active ingredient USTEKINUMAB, a human monoclonal antibody that selectively targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting the release of pro-inflammatory cytokines.

Key Benefits & Uses

Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Treatment of active psoriatic arthritis in adults.
Treatment of moderate to severe Crohn's disease in adults who have had an inadequate response or were intolerant to conventional therapy.

Active Ingredient & Action

USTEKINUMAB works by binding to the p40 subunit of IL-12 and IL-23, which are pro-inflammatory cytokines involved in the pathogenesis of psoriasis and other inflammatory conditions. By inhibiting the release of these cytokines, USTEKINUMAB reduces inflammation and slows down disease progression.

Important Notes

STEQEYMA IV is available by prescription only. Patients should carefully follow the dosing instructions and consult their doctor if they have any questions or concerns. Common side effects may include injection site reactions, upper respiratory tract infections, and fatigue. Patients should also inform their doctor about any pre-existing medical conditions, medications, or allergies before starting treatment with STEQEYMA IV.